 | |
Displaying lapatinib PowerPoint Presentations
Presentation Summary : Insights: Lapatinib as a monotherapy has modest but real activity in pts with trastuzumab-refractory disease. This activity can be enhanced, ...
Source : http://hematology.wustl.edu/conferences/presentations/Hu_2011-10-07.ppt
CAELYXTM (pegylated liposomal doxorubicin hydrochloride) PPT
Presentation Summary : Reference Text Lapatinib, a small molecule that is administered orally, inhibits the tyrosine kinase components of ErbB1 and ErbB2 receptors.
Source : http://www.sistersnetworkinc.org/documents/Metastatic_EdRiveraMD.ppt
Presentation Summary : Lapatinib Greater “trust” in its first and second line activity Increasing reassurance on low cardiotoxic potential Highlights 2006-2007 Trastuzumab in the ...
Source : http://www.esmo.org/fileadmin/media/presentations/831/LCT10001267.ppt
Allred IHC Score - Projects In Knowledge - Continuing Medical ... PPT
Presentation Summary : Abstract 1011. 0 20 40 60 80 100 0 20 40 60 80 100 P + L = paclitaxel + lapatinib; P = paclitaxel + placebo. .011 P-value 0.57 (0.34, 0.93) HR (95% CI) 5.8 8.1 ...
Source : http://www.projectsinknowledge.com/Activity/slides/1808.01.ppt
Hepatocellular Carcinoma - Epatocarcinoma HCC PPT
Presentation Summary : ... FGFR EGFR IGF-IR c-MET SHC GrB2 GEF Ras Site of action Erlotinib Gefitinib Lapatinib RAD001 Sorafenib Sunitinib x x x x x x x x x Receptor Cell Membrane c ...
Source : http://www.hcc-infohelp.org/Sorafenib%20Epidemiology.ppt
Presentation Summary : Currently, the OS benefit of Lapatinib has not been demonstrated. Note: Lapatinib was approved under accelerated approval. Study EGF 3008 : ...
Source : http://www.mbswonline.com/upload/presentation_5-26-2011-6-52-41.ppt
… Read Document - The Ohio State University Comprehensive ... PPT
Presentation Summary : ... GV1001 Sorafenib Flavopiridol Dasatinib Calcitriol Imatinib PTK787 AG-013736 Enzastaurin Entracept AZD 0530 Curcumin Lapatinib Celecoxib Phase III trials ...
Source : http://cancer.osu.edu/research/researcheducation/meetingsconferences/GIconference/Documents/elrayes.ppt
Presentation Summary : <QCcomment><QCcomment> N = 752 Capecitabine + Ixabepilone vs Ixabepilone Ixabepilone N = 324 Capecitabine + Lapatinib vs Capecitabine Lapatinib N = 529 Paclitaxel ...
Source : http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4332s1-03-Genentech.ppt
